IONpath Launches Research Services Offering Multiplexed Tissue Analysis to Empower Pharmaceutical Discovery and Development Programs

Food and Healthcare Press Releases Wednesday February 12, 2020 17:02
MENLO PARK, California--12 Feb--PRNewswire/InfoQuest

IONpath, Inc., today announces the launch of a dedicated service business providing access to their proprietary MIBIscope(TM) multiplexed imaging platform and its team of experts to support pharmaceutical and biotechnology companies working in immuno-oncology.

IONpath has previously provided custom research services to leading academic and pharmaceutical organizations as part of an Early Access Program. Now the company has formalized its intentions to become a partner of choice to those interrogating the tumor microenvironment to understand therapeutic mechanism of action and identify responder populations.

"We started this company because we love doing great science and working with great scientists," said Harris Fienberg, chief executive officer and co-founder, IONpath. "Our team is incredibly excited to enable the next generation of immunotherapy development on a massive scale."

Based in their global headquarters in Silicon Valley and serving clients from around the world, an expert team of engineers, pathologists and data scientists are leveraging the proprietary MIBIscope platform to help solve the most complex problems in immuno-oncology. The MIBIscope(TM) can simultaneously image forty or more individual proteins on a single slide with the reproducibility needed for large clinical studies. IONpath is building the capacity to stain, image and analyze over 15,000 highly multiplexed slides a year by the end of 2020. The company hopes to unlock valuable data about co-expression levels, proximity of cell populations and correlations to outcomes observed in patients to meaningfully contribute to the development of immunotherapies for partners across industry and academia.

If you or your company would be interested in learning more about what Research Services can do for your program, please contact us at research@ionpath.com to talk to our expert team or request a quote.
About IONpath, Inc.

IONpath, Inc. is revolutionizing tissue imaging to accelerate medical discovery and improve human health. The company's MIBIscope(TM) System, which utilizes Multiplexed Ion Beam Imaging (MIBI(TM)) technology, represents a transformative step in tissue imaging by simultaneously multiplexing 40+ markers with single cell resolution. Leading research institutes and biotech and pharmaceutical companies are using the MIBIscope in immuno-oncology, immunology and neuroscience research where high-fidelity multiplexed imaging data is needed. In addition to the MIBIscope System IONpath empowers the research and development initiatives of academic, biotech and pharmaceutical partners through IONpath Research Services.

Visit www.ionpath.com to find out more.
Contact:
Terri Hnatyszyn
305-803-0824
media@ionpath.com
Photo - https://mma.prnewswire.com/media/1088946/IONpath_Research_Services.jpg
Logo - https://mma.prnewswire.com/media/1088947/IONpath_Logo.jpg

Latest Press Release

Affinity discovers potent SARS-CoV-2 antibodies

Melbourne-based Affinity Biosciences Pty Ltd (Affinity), a privately held company focused on antibody discovery for cancer therapeutics, today announces the discovery of potent antibodies with therapeutic potential against COVID-19. In March, Affinity...

Traditional Chinese medicine tourism and health care base rising in north China's Taihang Mountains

Deep in the Taihang Mountains in north China, a group of workers are busy planting local authentic traditional Chinese medicines (TCM) in the Bian Que TCM Valley, the largest TCM planting base in Neiqiu County, Xingtai City, Hebei Province. The valley is...

CF PharmTech, Inc. Closes a US $50M Series F Financing to Accelerate the Commercialization of its Inhalation Products.

CF PharmTech, Inc. ("CF PharmTech") announced today that it has raised US $50M in Series F financing following its US $90M Series E financing in January of 2020, in total, successfully completing an equity investment deal of nearly US $140M within six...

Zhejiang Hisun Pharmaceutical: COVID-19 Pandemic Brought Under Control in China With Favipiravir Showing Excellent Clinical Results

COVID-19 has become a global pandemic. China's successful control of the pandemic has set a good example for other countries. Many have followed China to take effective measures like enforcing lockdowns and wearing masks have all been proved to be...

Almost Half of Children Are Not Always Using Soap When Washing Hands at School, New Survey by the Global Hygiene Council Finds

Leading hygiene experts are stressing the importance of effective hand hygiene measures and education in schools as children begin returning to educational settings following the COVID-19 pandemic The calls follow a new global survey conducted by The...

Related Topics